Filing Details
- Accession Number:
- 0000899243-21-041472
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-10-25 18:42:37
- Reporting Period:
- 2021-10-25
- Accepted Time:
- 2021-10-25 18:42:37
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1851194 | Ventyx Biosciences Inc. | VTYX | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1727703 | Aaron Royston | C/O Ventyx Biosciences, Inc. 662 Encinitas Blvd, Suite 250 Encinitas CA 92024 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-10-25 | 3,684,769 | $0.00 | 3,684,769 | No | 4 | C | Indirect | See footnote |
Common Stock | Acquisiton | 2021-10-25 | 312,500 | $16.00 | 3,997,269 | No | 4 | P | Indirect | See footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | See footnote |
No | 4 | P | Indirect | See footnote |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series A Preferred Stock | Disposition | 2021-10-25 | 3,289,742 | $0.00 | 3,289,742 | $0.00 |
Common Stock | Series B Preferred Stock | Disposition | 2021-10-25 | 395,027 | $0.00 | 395,027 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 1,014,267 | Indirect | See footnote |
Footnotes
- All shares of the preferred stock, par value $0.0001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.
- Shares held by venBio III. venBio GP is the sole general partner of venBio III. venBio Ltd is the sole general partner of venBio GP. The Reporting Person, Robert Adelman and Corey Goodman are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the shares held by venBio III. The Reporting Person disclaims beneficial ownership over the shares held by venBio III except to the extent of his pecuniary interest therein.
- Shares held by venBio SPV III, LLC ("venBio SPV"). venBio SPV is wholly owned and managed by venBio Global Strategic Fund III, L.P. ("venBio III"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership ("venBio GP") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company ("venBio Ltd") is the sole general partner of venBio GP. The Reporting Person, Robert Adelman and Corey Goodman are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the shares held by venBio SPV. The Reporting Person disclaims beneficial ownership over the shares held by venBio SPV except to the extent of his pecuniary interest therein.